Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

Por Fecher, Leslie A, Sharfman, William H
Publicado no Biologics (2015)

Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma

Por Lipson, Evan J., Bodell, Mabel A., Kraus, Edward S., Sharfman, William H.
Publicado no J Clin Oncol (2014)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

Por Jain, Animesh, Lipson, Evan J, Sharfman, William H, Brant, Steven R, Lazarev, Mark G
Publicado no World J Gastroenterol (2017)

Primary Small Cell Neuroendocrine Carcinoma of Paranasal Sinuses

Por Khan, Maliha, Nizami, Sobia, Mirrakhimov, Aibek E., Maughan, Benjamin, Bishop, Justin A., Sharfman, William H.
Publicado em 2014

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Por Lipson, Evan J., Lilo, Mohammed T., Ogurtsova, Aleksandra, Esandrio, Jessica, Xu, Haiying, Brothers, Patricia, Schollenberger, Megan, Sharfman, William H., Taube, Janis M.
Publicado no J Immunother Cancer (2017)

Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody

Por Lipson, Evan J., Sharfman, William H., Drake, Charles G., Wollner, Ira, Taube, Janis M., Anders, Robert A., Xu, Haiying, Yao, Sheng, Pons, Alice, Chen, Lieping, Pardoll, Drew M., Brahmer, Julie R., Topalian, Suzanne L.
Publicado em 2012

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Por Lipson, Evan J, Sharfman, William H, Chen, Shuming, McMiller, Tracee L, Pritchard, Theresa S, Salas, January T, Sartorius-Mergenthaler, Susan, Freed, Irwin, Ravi, Sowmya, Wang, Hao, Luber, Brandon, Sproul, Janice Davis, Taube, Janis M, Pardoll, Drew M, Topalian, Suzanne L
Publicado no J Transl Med (2015)

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Por Jimeno, Antonio, Weiss, Glen J., Miller, Wilson H., Gettinger, Scott, Eigl, Bernard J.C., Chang, Anne Lynne S., Dunbar, Joi, Devens, Shannon, Faia, Kerrie, Skliris, Georgios, Kutok, Jeff, Lewis, Karl D., Tibes, Raoul, Sharfman, William H., Ross, Robert W., Rudin, Charles M.
Publicado em 2013

A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics

Por Farasat, Sharifeh, Yu, Siegrid S., Neel, Victor A., Nehal, Kishwer S., Lardaro, Thomas, Mihm, Martin C., Byrd, David R., Balch, Charles M., Califano, Joseph A., Chuang, Alice Y., Sharfman, William H., Shah, Jatin P., Nghiem, Paul, Otley, Clark C., Tufaro, Anthony P., Johnson, Timothy M., Sober, Arthur J., Liégeois, Nanette J.
Publicado no J Am Acad Dermatol (2011)

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Por Brahmer, Julie R., Drake, Charles G., Wollner, Ira, Powderly, John D., Picus, Joel, Sharfman, William H., Stankevich, Elizabeth, Pons, Alice, Salay, Theresa M., McMiller, Tracee L., Gilson, Marta M., Wang, Changyu, Selby, Mark, Taube, Janis M., Anders, Robert, Chen, Lieping, Korman, Alan J., Pardoll, Drew M., Lowy, Israel, Topalian, Suzanne L.
Publicado no J Clin Oncol (2010)

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Por Topalian, Suzanne L., Sznol, Mario, McDermott, David F., Kluger, Harriet M., Carvajal, Richard D., Sharfman, William H., Brahmer, Julie R., Lawrence, Donald P., Atkins, Michael B., Powderly, John D., Leming, Philip D., Lipson, Evan J., Puzanov, Igor, Smith, David C., Taube, Janis M., Wigginton, Jon M., Kollia, Georgia D., Gupta, Ashok, Pardoll, Drew M., Sosman, Jeffrey A., Hodi, F. Stephen
Publicado no J Clin Oncol (2014)

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Por Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
Publicado no J Clin Oncol (2014)

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Por Nghiem, Paul T., Bhatia, Shailender, Lipson, Evan J., Kudchadkar, Ragini R., Miller, Natalie J., Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K., Daud, Adil, Fling, Steven P., Friedlander, Philip A., Kluger, Harriet M., Kohrt, Holbrook E., Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M., Reddy, Sunil A., Shantha, Erica M., Sharfman, William H., Sharon, Elad, Shemanski, Lynn R., Shinohara, Michi M., Sunshine, Joel C., Taube, Janis M., Thompson, John A., Townson, Steven M., Yearley, Jennifer H., Topalian, Suzanne L., Cheever, Martin A.
Publicado no N Engl J Med (2016)

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Por Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Carvajal, Richard D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Horn, Leora, Drake, Charles G., Pardoll, Drew M., Chen, Lieping, Sharfman, William H., Anders, Robert A., Taube, Janis M., McMiller, Tracee L., Xu, Haiying, Korman, Alan J., Jure-Kunkel, Maria, Agrawal, Shruti, McDonald, Daniel, Kollia, Georgia D., Gupta, Ashok, Wigginton, Jon M., Sznol, Mario
Publicado em 2012